Aardvark Therapeutics, Inc.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $68.11 | $76.65 | $63.15 | $73.36 | 40.39M |
| Jul 2, 2026 | $64.95 | $69.20 | $64.13 | $68.11 | 39.76M |
| Jul 1, 2026 | $64.54 | $65.43 | $63.78 | $64.95 | 23.86M |
| Jun 30, 2026 | $63.06 | $66.87 | $60.81 | $64.54 | 28.50M |
| Jun 29, 2026 | $65.37 | $67.38 | $61.41 | $63.06 | 20.60M |
| Jun 28, 2026 | $68.23 | $72.99 | $59.91 | $65.37 | 33.52M |
| Jun 27, 2026 | $69.99 | $72.89 | $66.70 | $68.23 | 50.02M |
| Jun 26, 2026 | $66.59 | $72.35 | $63.81 | $69.99 | 26.91M |
Company Overview
Aardvark Therapeutics, Inc. operates in the healthcare space within the Healthcare sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 14 · Independent 12 of 14| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 23 | Morgan Stanley | $127.35 | Neutral |
| Jun 13 | Citi | $81.44 | Overweight |
| Jun 7 | Mizuho | $99.67 | Buy |
| Jun 4 | Morgan Stanley | $112.20 | Reduce |
| May 20 | Goldman Sachs | $117.84 | Overweight |
| May 8 | Citi | $128.13 | Strong Buy |
Politician Trades
View allWhat's Happening Right Now
- Sep 17, 2026 · Lawsuit ↗ — Robbins LLP is investigating claims that Aardvark misled investors about the viability and efficacy of its lead drug candidate ARD-101.
- Sep 15, 2026 · Lawsuit ↗ — Pomerantz Law Firm announced the filing of a class action against Aardvark Therapeutics and certain of its officers and directors.
- Sep 18, 2026 · Lawsuit ↗ — Hagens Berman is soliciting investors for a securities fraud class action ahead of an October 13, 2026 lead plaintiff deadline.
- Sep 14, 2026 · Insider Activity ↗ — Sun Nelson disposed of 76,754 shares of Aardvark Therapeutics at prices between $5.00 and $5.18.
- Sep 16, 2026 · Investor Notice ↗ — A notice was issued to long-term shareholders of Aardvark regarding the ongoing situation.
Snapshot
Aardvark Therapeutics, Inc. (AARD) has no Form 10-K on file, so no revenue, profit, or balance-sheet figures are available for review at this time. In the absence of disclosed financials, the current news flow is dominated by a wave of securities class action announcements and law firm solicitations tied to allegations about the company's lead drug candidate, ARD-101. Multiple law firms, including Rosen, Hagens Berman, Levi & Korsinsky, Robbins LLP, Bragar Eagel & Squire, and Pomerantz, have issued investor alerts or filed suits with a lead plaintiff deadline of October 13, 2026. There is also a reported insider stock disposal by Sun Nelson at prices around $5.00-$5.18 per share. No fundamental financial data is currently available to assess the company's operating or balance-sheet position.
Bottom Line
With no financial filings available, investors have no fundamental data to gauge Aardvark's operating performance or balance sheet strength. The dominant near-term narrative is legal risk: a cluster of securities class actions alleging the company misrepresented the viability of its lead candidate ARD-101, with an October 13, 2026 lead plaintiff deadline looming. Until financial disclosures and litigation outcomes become clearer, the stock's risk profile is driven primarily by legal and reputational overhang rather than measurable fundamentals.